modelR01AD08
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Fluticasone | |
| ATC code: | R01AD08 | route: | intranasal |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 318 | L |
| clearance: | 1.1 | L/min |
| other parameters in model implementation | ||
Fluticasone is a synthetic corticosteroid with potent anti-inflammatory properties. It is commonly used as a nasal spray for the treatment of allergic rhinitis and as an inhaled medication for asthma and chronic obstructive pulmonary disease (COPD). Fluticasone is approved and widely used today in clinical practice.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers following intranasal administration of fluticasone propionate.
References
Wolthers, OD (2013). New patents of fixed combinations of nasal antihistamines and corticosteroids in allergic rhinitis. Recent patents on inflammation & allergy drug discovery 7(3) 223–228. DOI:10.2174/1872213x113079990019 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23862774
Wang, P, et al., & Li, X (2025). Pharmacokinetics and Bioequivalence of 2 Products of Fluticasone Propionate Nasal Spray in Healthy Chinese Subjects. Clinical pharmacology in drug development 14(5) 398–403. DOI:10.1002/cpdd.1507 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39828962
Chen, G, et al., & Wang, J (2025). Bioequivalence Study of 2 Formulations of Fluticasone Nasal Spray in Healthy Chinese Volunteers. Clinical pharmacology in drug development 14(3) 270–275. DOI:10.1002/cpdd.1505 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39789740
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)